Please login to the form below
Zentiva
This page shows the latest Zentiva news and features for those working in and with pharma, biotech and healthcare.
Sanofi warns of difficult few months as diabetes sales slump
said that the last few months have included the pipeline-building acquisitions of Bioverativ and Ablynx and the sale of its Zentiva generics business to a private equity group.
Latest news
-
Sanofi appoints ex-Roche Reed as new R&D head
Brandicourt has also demonstrated his commitment to pursuing the core pharma business at Sanofi by selling off its Zentiva generics business for 1.9bn ($2.4bn).
-
Sanofi sells European generics to Advent for $2.4bn
Sanofi has been looking to divest the Zentiva generics unit since 2016 as part of restructuring the business under chief executive Olivier Brandicourt, who said: “Transferring this business to Advent is ... Sanofi bought the foundations of its European
-
Ten new medicines recommended in Europe
Duloxetine Zentiva (duloxetine) - a copycat of Lilly's Cymbalta - for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder, also saw a nod from the EMA.
-
Three cancer immunotherapies amongst new CHMP approvals
Finally, two generic medicines gained positive opinions: Bortezomib Accord (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma and Pregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised
-
Orphan drugs in latest CHMP recommendations
Completing the positive opinions were two new informed consent applications: Sevelamer carbonate Zentiva (sevelamer) from Genzyme for the control of hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis and Rasagiline
More from news
Approximately 1 fully matching, plus 16 partially matching documents found.
Latest appointments
-
Karim Husny moves from Omega Pharma to Alliance Pharmaceuticals
He brings experience in over the counter and consumer healthcare having worked at several European pharmaceutical firms, including Laboratoire de la Mer, Pfizer and Sanofi's Zentiva business.
-
Watson selects global generics management team
Ramneborn has more than 20 years' experience in the pharmaceutical industry and joined Actavis from Zentiva, where he was vice president and a member of the board of directors since 2003.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Lilly’s Verzenio scores a win in early-stage breast cancer
- New study identifies drugs that are safe to use in COVID-19 treatment
- Researchers call on Pfizer to delay COVID-19 vaccine application
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Phase 1/2a results for J&J’s COVID-19 vaccine show early promise
- J&J advances COVID-19 vaccine into phase 3 testing
- Covid-19 redefines rules of customer engagement
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Aurora extends exclusive collaboration with Patient Intelligence Panel (PIP Health)
- Moderna’s COVID-19 vaccine generates strong immune response in older adults
- Regeneron’s COVID-19 antibody cocktail reduces viral load and alleviates symptoms
- What makes a great launch leader and launch team?
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Covid-19 redefines rules of customer engagement
- Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
- The concordance conundrum: understanding the complexities of behaviour change
- Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
Quick links
Infographics
